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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by deposition of amyloid
plaques and disruption of neural circuitry, leading to cognitive decline. Animal models of AD deposit senile plaques
and exhibit structural and functional deficits in neurons and neural networks. An effective treatment would prevent
or restore these deficits, including calcium dyshomeostasis observed with in-vivo imaging.
Methods: We examined the effects of DA-9803, a multimodal botanical drug, in 5XFAD and APP/PS1 transgenic mice
which underwent daily oral treatment with 30 or 100 mg/kg DA-9803 or vehicle alone. Behavioral testing and longitudinal
imaging of amyloid deposits and intracellular calcium in neurons with multiphoton microscopy was performed.
Results: Chronic administration of DA-9803 restored behavioral deficits in 5XFAD mice and reduced amyloid-β levels. DA-
9803 also prevented progressive amyloid plaque deposition in APP/PS1 mice. Elevated calcium, detected in a subset of
neurons before the treatment, was restored and served as a functional indicator of treatment efficacy in addition to the
behavioral readout. In contrast, mice treated with vehicle alone continued to progressively accumulate amyloid plaques
and calcium overload.
Conclusions: In summary, treatment with DA-9803 prevented structural and functional outcome measures in mouse
models of AD. Thus, DA-9803 shows promise as a novel therapeutic approach for Alzheimer’s disease.
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Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder and the most prevalent form of dementia
[1]. AD is defined by the presence of amyloid plaques
and neurofibrillary tangles in the brain [2]. Overwhelm-
ing evidence suggests that the aggregation of amyloid-
beta (Aβ) initiates a cascade of events that lead to for-
mation of amyloid plaques and neurofibrillary tangles
that culminate in loss of neurons [3]. Transgenic mouse
models that overexpress human amyloid precursor
protein (APP) develop Aβ-related pathologies such as
amyloid plaque deposition similar to those in AD pa-
tients [4–6]. Additionally, as these mice age, their cor-
tical neurons exhibit alterations in calcium homeostasis,
supporting the calcium hypothesis of AD [7–11]. Ap-
proximately 20% of neuronal processes exhibit aberrant
calcium homeostasis leading to elevated levels of resting
calcium, or calcium overload, in APP/PS1 mice aged 8–
10 months with substantial amyloid pathology, and this
is not related to the presenilin gene [11]. Calcium over-
load also correlates with disrupted neuronal structure
and function [11], so restoring calcium homeostasis
could serve as an indirect functional indicator of treat-
ment efficacy. Furthermore, it is well documented that
neuroinflammation is central to the progression of the
disease, although it is not clear whether it is a cause or
a consequence of the disease. An increased number of
reactive microglia and astrocytes are concentrated in
close proximity to amyloid plaques in humans and
mouse models [12–14]. Thus, an effective AD treatment
would halt Aβ deposition, restore intraneuronal calcium
to control levels, and improve the ability of neuroin-
flammatory cascades to respond to pathology.
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DA-9803 is a multimodal, botanical therapeutic cur-
rently in preclinical development by Dong-A ST that
shows nootropic promise. It is a well-controlled propri-
etary extract from Morus alba L. and the surface layer of
Poria cocos that contains multiple major and minor ac-
tive ingredients. Its pharmacokinetics and mechanism of
action are currently under study. The extract is carefully
and reproducibly prepared similar to other natural prod-
uct extracts [15]. Thus, the extract, with no obvious in-
dications of toxicity, is a potential drug candidate for the
treatment and prevention of AD.
This work tested the ability of DA-9803 to reverse the
structural and functional deficits in two separate AD
mouse models. 5XFAD mice show behavioral deficits as
they age, which was restored with DA-9803 treatment in
parallel with a decrease in Aβ levels measured with
ELISA. Multiphoton imaging in a separate cohort of
APP/PS1 mice treated with DA-9803 was used to moni-
tor the dynamics of plaque deposition [16] and neuronal
calcium levels in the cortex during a 2-month treatment
period [16, 17]. Treating young APP/PS1 mice with DA-
9803 halted Aβ plaque deposition and decreased the
number of neuronal processes exhibiting calcium over-
load. These results suggest that DA-9803 affects Aβ ag-
gregation as well as functional outcome measures in
mouse models, and warrants further investigation of this
promising therapeutic.
Methods
Animals and surgery
Five-month-old 5XFAD transgenic mice (five males/group)
were used for the behavioral analyses. 5XFAD transgenic
mice overexpress both mutant human APP(695) with the
Swedish (K670N, M671L), Florida (I716V), and London
(V717I) mutations as well as human PS1 harboring two
FAD mutations, M146L and L286V [6]. The behavioral ex-
periments were approved by Institutional Animal Care and
Use Committee of Dong-A ST and conducted according to
the IACUC guidelines.
Transgenic APPSwe/PS1dE9 mice were used for longi-
tudinal imaging studies (eight males, five females). APP/
PS1 mice overexpress the Swedish mutation in the APP
gene, as well as the delta E9 mutation in the PS1 gene
[5]. The studies were conducted in compliance with
Massachusetts General Hospital Animal Care and Use
Committee and NIH guidelines for the use of experi-
mental animals.
At 5 months of age, the APP/PS1 animals underwent
intracortical virus injections followed by craniotomies as
described previously [18, 19]. Briefly, each animal was
anesthetized with 2% isoflurane and placed in a sterotaxic
apparatus. Body temperature was maintained with a heat-
ing pad throughout the course of anesthesia. The skin
over the skull was disinfected with betadine and isopropyl
alcohol, and then cut to reveal the skull. Burr holes were
drilled through the skull in each hemisphere with the fol-
lowing coordinates: A–P –3 mm, M–L –1 mm, D–V –
0.8 mm with respect to the bregma. Using a Hamilton syr-
inge, 1.5 μl of AAV8 Yellow Cameleon 3.6 (YC3.6) (U.
Penn Viral Core) was injected 0.8 mm below the dura in
both burr holes at a rate of 130 nl/min to target excitatory
neurons in the somatosensory cortex. YC3.6 is a genetic-
ally encoded ratiometric calcium indicator that reports
calcium concentrations quantitatively [11, 20]. A cranial
window was then installed by first performing a round
craniotomy over the somatosensory cortex. The area over
the brain was covered with an 8-mm glass coverslip and
fixed with a mixture of crazy glue and dental cement [18,
19, 21]. Each animal remained on a heating pad while re-
covering from anesthesia. To allow for YC3.6 expression
and to limit an inflammatory response associated with the
craniotomy interfering with multiphoton imaging, DA-
9803 treatment commenced 4 weeks after virus injections
and installation of cranial windows. Mice were 6 months
old at this point.
Chronic DA-9803 treatment
Each 5XFAD mouse was assigned randomly to either the
vehicle or the DA-9803 treatment condition for the be-
havioral studies. Then 200 μl of the vehicle or the DA-
9803 solution was administered via oral gavage daily.
DA-9803 is a botanical drug that can be dissolved in sa-
line solution. The vehicle consisted of phosphate buff-
ered saline (PBS) and hydroxypropyl methyl cellulose
(HPMC). The drug treatment was composed of the ve-
hicle solution as well as DA-9803. Animals in the drug
condition received doses of either 30 or 100 mg/kg DA-
9803. After 4 weeks of daily gavage treatment, the
5XFAD mice were subjected to the Y-maze and the pas-
sive avoidance tests. Animals were subsequently eutha-
nized and their brains processed for biochemistry.
For the longitudinal imaging experiments, APP/PS1
animals were assigned randomly to either the vehicle or
the DA-9803 treatment condition. Then 300 μl of the
vehicle or the DA-9803 solution was administered by
oral gavage daily. The vehicle consisted of PBS and
HPMC. DA-9803 was added to the vehicle formulation
for administration to the treated mice. Animals in the
drug condition received a dose of 100 mg/kg DA-9803.
Daily gavage treatment commenced after the first multi-
photon imaging session. Animals were subsequently im-
aged 2, 4, and 8 weeks after the first imaging session.
Daily gavage treatment was continued until the last im-
aging session, after which the animals were perfused
transcardially with PBS, and their brains extracted and
processed for immunohistochemistry. Of the 13 animals
that were imaged, seven were treated with the vehicle
and six were treated with DA-9803.
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Multiphoton imaging and data acquisition
The day prior to the first imaging session, mice were
injected intraperitoneally with 4 mg/kg methoxy-XO4 to
label amyloid plaques [11, 22]. Texas Red-labeled dex-
tran was injected via the retro-orbital sinus to provide a
fluorescent angiogram. Prior to subsequent imaging ses-
sions, animals were reinjected with methoxy-XO4 to
label newly appeared amyloid plaques. Imaging of amyl-
oid plaques and YC3.6-positive neurons was performed
using an Olympus Fluoview 1000MPE mounted on an
Olympus BX61WI upright microscope. A 25× water
immersion objective (NA = 1.05) was used for imaging.
A mode-locked titanium:sapphire laser (MaiTai; Spectra-
Physics, Fremont, CA, USA) generated two-photon
fluorescence with either 800 or 860 nm excitation.
Amyloid plaque pathology was imaged using 800 nm ex-
citation at 1× zoom. YC3.6 was imaged using 860 nm
excitation at 1×, 2×, and 5× zoom. Laser power was kept
below 30 mW to avoid phototoxicity.
After each imaging session, mice were allowed to re-
cover from anesthesia on a heating pad. At the end of
the last imaging session, mice were euthanized with
CO2, perfused with 4% paraformaldehyde in PBS, and
fixed with 4% paraformaldehyde and 15% glycerol cryo-
protectant overnight. Brains were frozen in Optimal
Cutting Temperature compound (OCT), cut into 20-μm
coronal sections on a cryostat, and mounted onto slides.
Image processing and data analysis
Image stacks acquired in vivo were analyzed using Ima-
geJ software (http://rsbweb.nih.gov/ij/). Images were an-
alyzed to determine amyloid plaque numbers, amyloid
plaque burden, and resting calcium levels within individ-
ual neuronal processes (neurites). The same neurites
were followed longitudinally to determine changes in
calcium levels in each individual, identified neurite.
Neurites that were not present in all four imaging ses-
sions were excluded from analysis. For amyloid plaque
analysis, each z-stack was processed into a maximum in-
tensity projection. To determine the amyloid plaque
number, amyloid plaques were counted manually in each
projected image. To calculate the amyloid burden, each
projected image was thresholded, segmented, and the
percentage area occupied by amyloid was measured. Any
signal from the amyloid lining the blood vessels, cerebral
amyloid angiopathy, was excluded from analysis.
YC3.6 images were also analyzed using ImageJ. YC3.6
is a FRET probe, composed of a donor, cyan fluorescent
protein (CFP), and an acceptor, yellow fluorescent pro-
tein (YFP) [20]. Intraneuronal concentrations were de-
termined from the ratio of YFP to CFP. The higher the
calcium concentration, the higher the ratio of YFP to
CFP. The background for each channel was calculated
by the mode of the intensities of the last slice of each
volume and was subtracted from its respective channel.
A median filter with a radius of 2 was applied and the
fluorescence intensity of YFP was divided by CFP to cre-
ate a ratio image. Neurites were identified manually and
selected using the ‘free hand’ tool on ImageJ in the YFP
images to minimize bias based on the calcium concen-
tration. These neuronal regions of interest (ROIs) were
then exported to the ratio images and the YFP/CFP ra-
tios calculated. The relative change in YFP/CFP ratio
(ΔR/Ri) was calculated by tracking the same neurites
throughout all four imaging sessions. YFP/CFP ratios
were converted to [Ca2+] with standard equations using
the in-situ Kd and Hill coefficient for YC3.6 determined
previously [11]. Pseudocolored images were created
using Matlab based on the calcium concentration using
the empirical Rmin and Rmax. The ratio values were used
to determine the hue and saturation (color) and the
brightness values were used to determine the value (in-
tensity) in the pseudocolored images.
Immunohistochemistry
Twenty-micrometer transverse coronal sections of
mouse brain underwent antigen retrieval in citrate buf-
fer. The coronal sections were then permeabilized with
Triton X-100, blocked with normal goat serum (NGS),
and incubated with the various primary antibodies: 6E10
(monoclonal 6E10, 1:500; Covance), IBA1 (rabbit anti-
Iba1, 1:2000; Wako), glial fibrillary acidic protein (GFAP)
(mouse anti-GFAP, 1:200; Thermo Scientific), and MAP2
(mouse anti-MAP2, 1:100; Abcam) for 2 hours at room
temperature. The coronal sections were then incubated
with the respective secondary antibodies for 1 hour and
mounted with ProLong Antifade reagent (Invitrogen).
Postmortem image analysis
To image amyloid plaque burden post mortem, images
of entire cortical hemispheres or hippocampi were ac-
quired using an inverted Zeiss microscope with a 10×
objective. Images were analyzed using ImageJ. Methoxy-
XO4-labeled plaques were thresholded and the amyloid
burden was calculated as a percentage of the cortical (or
hippocampal) area.
GFAP, 6E10, MAP2, and IBA1-stained slides were also
imaged using an inverted Zeiss microscope at 20× and 40×
zoom. The objective was either centered around a single
plaque or positioned over an area lacking plaques. Micro-
glia and astrocytes present in the field of view were counted
manually. Microglial and astrocytic process length and cell
body diameters were analyzed using ImageJ.
Y-maze test
The Y-maze consisted of three black, opaque, plastic
arms (5 cm × 30 cm × 12 cm) 120° from each other. The
5XFAD mice were placed in the center and were allowed
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to explore all three arms. The number of arm entries
and number of triads (a triad constituted subsequent en-
tries into three separate arms) were recorded to calculate
the percentage of alternation. An entry was defined as
all four appendages entering a Y-maze arm. Alternation
behavior was defined as the number of triads divided by
the number of arm entries minus 2 and multiplied by
100.
Passive avoidance test
The passive avoidance chamber was divided into a white
(light) and a black (dark) compartment (both 20 cm ×
20 cm × 20 cm). The light compartment contained a 50-
W electric lamp. The floor of the dark department con-
tained a number of 2-mm stainless steel rods spaced
1 cm apart. Each mouse was placed in the light compart-
ment. The door separating the two compartments was
opened 10 seconds later. Once the mouse entered the
dark compartment, the door closed and an electrical foot
shock (0.1 mA/10 g) was delivered through the grid floor
for 3 seconds. Twenty-four hours after the training trial,
mice were placed in the light chamber for testing. La-
tency was defined as the time it took for a mouse to
enter the dark chamber after the door separating the
two compartments opened.
Amyloid-beta ELISAs
Total (soluble and insoluble) Aβ40 and Aβ42 levels were
detected using the Aβ40 or Aβ42 sandwich ELISA kits.
Each 5XFAD cerebral cortex was homogenized in ice-
cold buffer and centrifuged at 14,000 × g for 30 minutes
at 4 °C to isolate Aβ. The resulting supernatants were
used for the immunoassay. Standards and tissue samples
were incubated in rabbit anti-mouse Aβ40 or Aβ42 poly-
clonal antibody-precoated 96-well immunoplates over-
night at 4 °C (KMB3481 and KMB3441; Invitrogen). The
plates were incubated with anti-rabbit IgG HRP for
30 minutes at room temperature. After washing, the
plates were incubated with stabilized Chromogen for
30 minutes in the dark. Stop solution was then added to
each well. The plates were read at 450 nm using a spec-
trophotometer (Spectramax microplate reader; Molecu-
lar Devices). Concentrations of Aβ40 or Aβ42 were
determined in the sample solution using Aβ40 or Aβ42
standard calibration curves. The protein from the sam-
ples was normalized using the Bio-Rad assay for total
protein determination.
Statistics
Statistical analyses were conducted in GraphPad 5.0.
Data were expressed as mean ± SEM. Datasets were
checked for normality (Shapiro–Wilk normality test or
Kolmogorov–Smirnov test) and appropriate statistical
tests were used (parametric t test or ANOVAs for
normally distributed data, Mann–Whitney or Kruskal–
Wallis test for nonparametric data). p < 0.05 was consid-
ered significant.
Results
One-month daily treatment with 30 mg/kg and 100 mg/
kg DA-9803 restores behavioral deficits and decreases Aβ
peptide levels in 5XFAD mice
5XFAD mice were used to determine the effect of DA-
9803 treatment on functional recovery as well as Aβ40
and Aβ42 levels in the cerebral cortex. Mice were
treated via daily gavage with the vehicle, 30 mg/kg DA-
9803, or 100 mg/kg DA-9803. Animal behavior was
monitored using the Y-maze and passive avoidance para-
digms. Prior to treatment, 5XFAD mice, regardless of
their assigned treatment condition, showed impairment
as a function of decreased alternation behavior in the Y-
maze, consistent with the literature (Fig. 1a, ANOVA
followed by Student–Newman–Keuls method, n = 5
mice/group) [6]. After 1 month of treatment, the 30 mg/
kg-treated and 100 mg/kg-treated mice showed im-
provement in alternation behavior between the arms of
the Y-maze compared to the vehicle-treated 5XFAD
mice (Fig. 1b, ANOVA followed by Student–Newman–
Keuls method, n = 5 mice/group). Moreover, animals in
the 100 mg/kg condition recovered to the levels of wild-
type controls (average of 71.7 ± 4.0% and 74.0 ± 6.2% re-
spectively) (Fig. 1b). 5XFAD mice showed impairment in
the passive avoidance task as well, spending 124.8 ±
20.3 seconds in the light compartment before returning
to the dark compartment when treated with vehicle
compared to 300.0 ± 0.0 seconds for the wildtype mice
(Fig. 1c, individual t tests, n = 5 mice/group). The
30 mg/kg-treated and 100 mg/kg-treated mice spent sig-
nificantly longer periods of time in the light compart-
ment compared to the vehicle-treated mice (189.6 ±
41.1 seconds and 195.0 ± 13.71 seconds respectively
compared to 124.8 ± 20.3 seconds), indicative of func-
tional recovery (Fig. 1c). Thus, 1-month 30 mg/kg and
100 mg/kg DA-9803 treatment improves the behavioral
deficit in the Y-maze and the passive avoidance task in
5XFAD mice, suggesting that DA-9803 has beneficial ef-
fects in these animals.
To investigate the effect of DA-9803 treatment on Aβ,
the Aβ40 and Aβ42 levels were measured using ELISAs in
5XFAD mice. Aβ40 and Aβ42 analyses showed similar
trends. Aβ40 and Aβ42 levels were the lowest in wildtype
mice (134.6 ± 60 pg/mg and 2.44 ± 0.24 pg/mg respect-
ively) (Fig. 1d, e). Vehicle-treated and 30 mg/kg-treated
mice had comparable levels of Aβ40 and Aβ42 after treat-
ment (vehicle-treated mice: 546.4 ± 48.8 pg/mg of Aβ40
and 50.7 ± 2.1 pg/mg of Aβ42; 30 mg/kg-treated mice:
521.4 ± 99.9 pg/mg of Aβ40 and 52.6 ± 8.3 pg/mg of
Aβ42) (Fig. 1d, e). The 100 mg/kg treatment significantly
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lowered the levels of Aβ40 and Aβ42 compared to the ve-
hicle (297.3 ± 26.7 pg/mg of Aβ40 and 34.1 ± 3.9 pg/mg of
Aβ42, ANOVA followed by Newman–Keuls post-hoc test,
n = 5 cortices/group) (Fig. 1d, e). These data suggest that
DA-9803 is reducing production or increasing clearance
of Aβ40 and Aβ42 via a dose-dependent mechanism.
Two-month daily treatment with DA-9803 halts plaque
deposition in-vivo in APP/PS1 mice
APP/PS1 mice were used to monitor the longitudinal effect
of DA-9803 treatment on plaque deposition. Mice were
treated via daily gavage with either the vehicle or 100 mg/kg
DA-9803 for 2 months (Fig. 2a). Individual plaques were
imaged over time with multiphoton microscopy (Fig. 2b-g).
Angiograms were used as fiducial markers to find the pla-
ques in the same locations over time (Fig. 2b, e). Mice in
the vehicle and the drug conditions started with a similar
number of plaques in the somatosensory cortex: vehicle-
treated mice exhibited 86 ± 17 plaques/mm3 while DA-
9803-treated mice had 89 ± 9 plaques/mm3 (mean ± SEM)
at baseline (Fig. 2h). Throughout the 2-month treatment
period, animals treated with the vehicle exhibited an in-
crease in the number of amyloid plaques accumulating to
an average of 140 ± 45 plaques/mm3 by the end of treat-
ment, statistically different from baseline (mean ± SEM,
Mann–Whitney test p < 0.001, n = 33 z-stacks in six mice
treated with vehicle) (Fig. 2h). Conversely, animals treated
with DA-9803 exhibited a decrease in amyloid plaque num-
ber and thus showed both prevention of plaque deposition
and plaque clearance (average of 67 ± 20 plaques/mm3 at
the end of DA-9803 treatment, significantly different from
baseline, Mann–Whitney test p < 0.01, n = 30 z-stacks in six
Fig. 1 Chronic treatment with DA-9803 restores behavioral deficits and decreases Aβ levels in cortices of 5XFAD mice. a, b Alternation behavior
in a Y-maze before (a) and after (b) 4-week chronic DA-9803 treatment in 5-month-old 5XFAD mice (n = 5 mice/group). c Latency of entry into
the dark compartment on a passive avoidance test after 4-week DA-9803 treatment (n = 5 mice/group). d, e Total Aβ40 (d) and Aβ42 (e) levels in
cortices of 5XFAD mice after 4-week DA-9803 treatment (n = 5 mice/group). Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. n.s. not significant,
Aβ amyloid-beta
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Fig. 2 Chronic treatment with DA-9803 slows plaque deposition and results in mild clearance of amyloid plaques in APP/PS1 mice. a Protocol for
chronic gavage treatment of DA-9803 (n = 6) or control compound (n = 6) in 6-month-old APP/PS1 mice. Methoxy-XO4 injected intraperitoneally (IP)
before each imaging session. b–d Two-photon images of an angiogram (b) and of methoxy-positive amyloid plaques taken at baseline (c) and after
8 weeks of treatment (d) of a mouse treated with control compound. e–g Two-photon images of an angiogram (e) and of methoxy-positive amyloid
plaques taken at baseline (f) and after 8 weeks of treatment (g) of a mouse treated with DA-9803. h, k Amyloid plaque number (h) and amyloid plaque
burden (k) during the course of 8-week treatment across conditions. Amyloid plaque burden and plaque number values compared to baseline values
via nonparametric Mann–Whitney test. i, l Amyloid plaque number (i) and amyloid plaque burden (l) after 8 weeks of treatment across conditions. j, m
Change in amyloid plaque number (j) and burden (m) at the end of treatment compared to baseline. Scale bar, 100 μm. Mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001
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mice treated with DA-9803) (Fig. 2h). Thus, the rates of
amyloid plaque deposition were different between the two
conditions (simple linear regression p < 0.05) (Fig. 2h). By
the end of treatment, the number of amyloid plaques was
significantly lower in DA-9803-treated compared to vehicle-
treated animals (Fig. 2i). Likewise, the amyloid burden,
which was similar at the beginning of treatment, increased
in the vehicle condition and decreased in the drug condition
(Fig. 2k). Hence, amyloid plaque burden was significantly
lower after the DA-9803 treatment compared to the vehicle
(Mann–Whitney test p < 0.001, n = 30 z-stacks in six mice
treated with DA-9803, n = 33 z-stacks in six mice treated
with vehicle; Fig. 2l). Therefore, DA-9803-treated mice ex-
hibited a 21.6 ± 11.94% reduction in amyloid plaque number
compared to baseline, while vehicle-treated mice presented
a 72.13 ± 27.85% increase (Fig. 2j). Similarly, amyloid plaque
burden decreased by the end of the DA-9803 treatment
compared to baseline, while increasing in the vehicle condi-
tion (Fig. 2m). Thus, daily oral treatment with DA-9803
halted plaque deposition and led to a reduction in amyloid
plaque number and amyloid plaque burden in APP/PS1
mice over the 2-month period.
To confirm the in-vivo findings, immunohistochemistry
with the anti-Aβ antibody 6E10 was performed on the 20-
μm thick coronal sections of brains isolated from animals
that underwent amyloid imaging in vivo. Amyloid plaque
burden was visualized ex vivo with the methoxy-XO4 sig-
nal that remained from in-vivo imaging as well as with
6E10. Methoxy-XO4 labeling colocalized with 6E10 immu-
nostaining in vehicle-treated animals (Fig. 3a–c) and those
treated with DA-9803 (Fig. 3d-f). Methoxy-XO4 labeled
dense core plaques, while 6E10 immunolabeled the Aβ-
including and surrounding dense core plaques (Fig. 3c, f),
similar to earlier reports [22, 23]. We analyzed 6E10-
labeled and methoxy-XO4-labeled amyloid burden in the
cortices of mice treated with DA-9803 and the vehicle (n =
19 cortical sections in six mice treated with DA-9803, n =
20 cortical sections in six mice treated with vehicle). The
amyloid burden detected with 6E10 in DA-9803-treated
mice was significantly lower than the amyloid burden in
vehicle-treated mice (0.75 ± 0.10% plaque load vs 1.4 ±
0.28% plaque load, Mann–Whitney test p < 0.05) (Fig. 3g).
Likewise, the amyloid burden detected with methoxy-XO4
in DA-9803-treated mice was significantly lower than the
amyloid burden in vehicle-treated mice in the cortex (0.09
± 0.02% plaque load vs 0.22 ± 0.04% plaque load, Mann–
Whitney test p < 0.05) (Fig. 3h) and the hippocampus
(0.03 ± 0.01% plaque load vs 0.14 ± 0.03% plaque load)
Fig. 3 DA-9803-treated mice had less postmortem cortical Aβ plaque load than vehicle-treated APP/PS1 mice. a–c Confocal microscope images
of 6E10-positive (a), methoxy-XO4-labeled (b), and colabeled (c) plaques in the vehicle condition. d–f Confocal microscope images of 6E10-
stained (d), methoxy-XO4-labeled (e) and colabeled (f) plaques in the vehicle condition. g Percentage of cortex occupied by 6E10-positive Aβ
across conditions. h Percentage of cortex occupied by methoxy-XO4-positive plaques across conditions. Scale bar, 100 μm. Mean ± SEM. *p < 0.05
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(Additional file 2: Figure S2). These data confirm the re-
sults from the in-vivo imaging experiments.
To test whether DA-9803 or vehicle interfered chemically
with methoxy-XO4 binding to plaques, fixed postmortem
brain sections containing plaques were preincubated with
either 10 mg/ml DA-9803, vehicle, or PBS, each followed
by incubation with 4 mg/kg methoxy-XO4. The fluores-
cence intensity of methoxy-XO4 was comparable in all
three conditions, indicating that DA-9803 did not interfere
with methoxy-XO4 binding to amyloid plaques (Additional
file 1: Figure S1). These data suggest that DA-9803 had a
biological effect on amyloid plaque clearance rather than a
direct chemical interference preventing visualization of
amyloid plaques during imaging.
Chronic treatment decreases the number of neurites with
calcium overload in APP/PS1 mice
Calcium homeostasis is necessary for proper neuronal func-
tion. Aberrant levels of intraneuronal calcium have been
linked to altered APP processing, synaptic dysfunction, and
AD symptoms in humans [24]. A higher proportion of neu-
rons exhibit elevated levels of calcium (calcium overload) in
aged APP/PS1 mice compared to wildtype littermates [11].
We analyzed neuronal calcium in vivo using the calcium
sensor Yellow Cameleon 3.6 (YC3.6) to determine whether
chronic DA-9803 treatment would restore the calcium
levels to normal in neuronal processes, or neurites, exhibit-
ing calcium overload. Elevated calcium levels or calcium
overload was defined as calcium concentrations two stand-
ard deviations greater than the average calcium concentra-
tion within the neurons in wildtype mice. Thus, a neuron
with YFP/CFP ratio greater than 1.79, and a respective cal-
cium concentration greater than 235 nM, was defined to
exhibit calcium overload (Fig. 4a, yellow arrows pointing to
red neurites). At baseline, prior to treatment, 6% of neurites
in the drug group and 6% of neurites in the vehicle group
exhibited calcium overload (Fig. 4c, d, see red boxes).
We collected additional resting calcium data during the
subsequent imaging sessions, at 2, 4, and 8 weeks after
treatment onset. Fluorescent angiograms were used to
provide fiduciary markers to ensure the same individual
neurites were identified across imaging sessions. After
2 months of treatment, the percentage of neurites with
calcium overload decreased to 2% of neurites in mice
treated with DA-9803 (Fig. 4b, d, e). Conversely, the per-
centage of overloaded neurites increased to 11% in mice
treated with vehicle alone (Fig. 4a, c, e). Since the same
neurites were tracked throughout the 2 months, the de-
crease in the number of overloaded neurites was a result
of a genuine calcium restoration and not a result of neur-
ite loss. Therefore, these data suggest that chronic treat-
ment with DA-9803 selectively rescued overloaded
neurites by restoring their baseline calcium and prevented
additional neurites from exhibiting calcium overload.
Chronic treatment with DA-9803 induces morphological
transformation in astrocytes and microglia in APP/PS1
mice
Activation of astrocytes and microglia has been detected in
brains from AD patients and APP/PS1 mice [12, 14, 25].
To determine the effect of DA-9803 on astrogliosis, 20-μm
postmortem brain sections of the vehicle-treated and DA-
9803-treated mice were immunostained with anti-glial fi-
brillary acidic protein (GFAP) antibody (Fig. 5a, d, e, h)
[26]. The number of GFAP-positive astrocytes in the cortex
of these animals did not differ between vehicle-treated and
DA-9803-treated mice (Fig. 5i). However, reactive astro-
cytes in both conditions were more likely to cluster around
plaques, as described previously (Fig. 5i) [27]. The brain
sections were also immunostained with an anti-Iba1 anti-
body to examine microglial reactivity (Fig. 5b, d, f, h) [28].
We found no difference in Iba1-positive microglia number
in DA-9803-treated and vehicle-treated animals (Fig. 5j).
The number of microglia was increased in close proximity
to plaques (Fig. 5j). MAP2 immunostaining revealed no ob-
vious changes in neuronal morphology or any indication of
toxicity (Additional file 2: Figure S2).
To determine the extent of astrocytic and microglial ac-
tivation, we performed quantitative analysis of glial
morphology. When treated with vehicle, astrocytes exhib-
ited lengthy processes and small cell bodies (Fig. 5k-n). In
contrast, DA-9803 treatment resulted in shortening of
astrocytic processes and enlargement of cell bodies, con-
sistent with activation of astrogliosis [29] (Fig. 5l-n). Simi-
larly, DA-9803-treated microglia exhibited shortening of
their processes and an increase in the cell body diameter
(Fig. 5o-r), potentially suggesting a transition to a phago-
cytic state [30, 31].
These results suggest that DA-9803 induces activation
of astrocytes and microglia, and possibly transitions glia
to a state prone to Aβ phagocytosis and its clearance.
Discussion
We assessed the effects of a multimodal botanical extract,
DA-9803, on behavioral deficits in 5XFAD mice as well
as amyloid pathology, neuronal calcium homeostasis, and
neuroinflammation in APP/PS1 mice. DA-9803 is a
therapeutic candidate currently in preclinical develop-
ment for the treatment or prevention of AD, with no ob-
vious indications of toxicity. The study followed two
protocols. First, 5XFAD animals underwent a 1-month
gavage treatment with DA-9803 or vehicle control daily.
Behavior was assessed using passive avoidance and Y-
maze paradigms. ELISAs were used to determine Aβ40
and Aβ42 levels in the cortex. In the second protocol,
APP/PS1 animals were treated for 2 months with daily
oral treatment of DA-9803 or vehicle control. Multipho-
ton microscopy was used to monitor plaques and intra-
neuronal calcium levels longitudinally in the animals.
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Postmortem plaque load and neuroinflammation were
also assessed. Chronic DA-9803 treatment reversed the
behavioral impairments observed in 5XFAD mice. It also
decreased Aβ40 and Aβ42 levels as well as the plaque
load in the cortex. The percentage of neurites that exhib-
ited high levels of intracellular calcium was lower in
drug-treated compared to the control-treated animals.
Furthermore, DA-9803 treatment led to morphological
changes in astrocytes and microglia suggesting a transi-
tion to a phagocytic state.
Five-month-old 5XFAD mice were tested using the
Y-maze and passive avoidance techniques after 1-
month 30 mg/kg and 100 mg/kg DA-9803 treatment.
The animals that were treated with the vehicle alone
were significantly impaired in both paradigms and
had elevated levels of Aβ40 and Aβ42 compared to
the wildtype mice. Both the 30 mg/kg-treated and
the 100 mg/kg-treated animals performed better
than their vehicle-treated counterparts on the behav-
ioral tests. Moreover, there was no statistical
Fig. 4 Calcium overload in DA-9803-treated mice is significantly decreased after 8 weeks of treatment. a, b Two-photon images of cortical neurites,
pseudocolored according to neuronal [Ca2+] concentration and intensity, in vehicle-treated (a) and DA-9803-treated (b) mice. Red neurites exhibit elevated
levels of calcium, blue neurites exhibit normal calcium levels. Yellow arrows denote overloaded neurites. c, d Histograms of neurite YC3.6 ratios for APP/
PS1 mice in the vehicle (c) and DA-9803 (d) conditions. n= 361 neurites in six mice in vehicle condition. n= 290 neurites in five mice in DA-9803 condition.
e Percentage of neurites exhibiting calcium overload across conditions after 8 weeks of treatment. Scale bar, 10 μm. Mean ± SEM. *p< 0.05. YFP yellow
fluorescent protein, CFP cyan fluorescent protein
Pagnier et al. Alzheimer's Research & Therapy  (2018) 10:11 Page 9 of 13
difference between the 30 mg/kg-treated and
100 mg/kg-treated animals, implying that the
30 mg/kg dose was sufficient for behavioral im-
provement. Interestingly, 100 mg/kg treatment re-
duced cortical Aβ40 and Aβ42 levels while 30 mg/kg
treatment failed to do so. These results indicate that
besides targeting Aβ40 and Aβ42, DA-9803 could
affect additional pathways that led to improvement
in the behavioral tests, supporting the multimodal
nature of DA-9803.
Fig. 5 IBA1 and GFAP immunoreactivity after treatment with DA-9803 and vehicle. a–d Fluorescent images of GFAP-positive astrocytes (a), IBA1-positive
microglia (b), methoxy-XO4-labeled plaques (c), and colocalization of GFAP, IBA1, and methoxy-XO4 (d) in APP/PS1 mice treated with vehicle compound.
e–h Fluorescent microscope images of GFAP-positive astrocytes (e), IBA1-positive microglia (f), methoxy-XO4-labeled plaques (g), and colocalization of
GFAP, IBA1, and methoxy-XO4 (h) in APP/PS1 mice treated daily with 100 mg/kg DA-9803. Scale bar, 20 μm. i Average number of astrocytes in close
proximity (plaque) and away from plaques (no plaque) in a field of view across conditions. j Average number of microglia in close proximity (plaque) and
away from plaques (no plaque) in a field of view across conditions. k, l High-magnification fluorescent images of GFAP-positive astrocytes treated with
vehicle (k) and DA-9803 (l). m Astrocyte process length across conditions. n Astrocyte cell body diameter across conditions. o, p High magnification
fluorescent images of IBA1-positive microglia treated with vehicle (o) and DA-9803 (p). q Microglial process length across conditions. r Microglial cell body
diameter across conditions. Scale bar, 10 μm. Mean ± SEM. *p< 0.05, ***p< 0.001. n.s. not significant, GFAP glial fibrillary acidic protein
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Individual plaques were tracked longitudinally during
four separate imaging sessions throughout the 2-month
drug treatment in the APP/PS1 animals. Mice treated with
the vehicle alone exhibited an increase in both amyloid
plaque number and burden over time, characteristic of
this amyloidosis model [32]. The DA-9803-treated mice
developed a limited number of new plaques in the course
of the 2-month treatment compared to the vehicle-treated
animals. This resulted in the DA-9803-treated animals
exhibiting a lower plaque number and burden compared
to the vehicle-treated mice at the end of the treatment.
This result was confirmed in postmortem coronal sections
of brain on a more global scale with measures of both
total cortical and hippocampal amyloid plaque burden.
These findings complement the immunoassay results in
the 5XFAD mice exhibiting lower levels of Aβ40 and
Aβ42 after 100 mg/kg DA-9803 treatment. Taken to-
gether, we demonstrated that DA-9803 treatment rescued
behavioral deficits, prevented progression of amyloid
plaque deposition, and led to clearance of Aβ in transgenic
mouse models of AD.
The mechanisms by which DA-9803 prevented plaque
deposition and/or promoted plaque clearance was un-
known. DA-9803 could have inhibited Aβ aggregation or
synthesis. Alternatively, DA-9803 could have accelerated
degradation or clearance of Aβ. Regardless of the exact
mechanisms, targeting Aβ could prevent/slow progres-
sion of AD, since it is likely that Aβ initiates the cascade
of AD pathology [33–35]. Aβ clearance could explain
the decreased plaque load in the DA-9803-treated ani-
mals. The current work, however, began with young
mice exhibiting sparse plaque load, and instances of
plaque clearance were rare. Future studies analyzing the
effects of DA-9803 in older transgenic animals with con-
siderable plaque load will be instrumental in testing the
treatment efficacy of DA-9803 as opposed to a preven-
tion measure for AD that was tested in the present
study. Also, the mechanisms of action of DA-9803 will
be investigated in future studies.
In addition, DA-9803’s effect on calcium homeostasis
was assessed in vivo. Aβ has been shown to disrupt cal-
cium homeostasis that resulted in neuronal calcium eleva-
tions [11]. Hence, restoration of intraneuronal calcium
serves as an indirect functional readout of treatment effi-
cacy. Longitudinal imaging with multiphoton microscopy
allowed us to track individually identified neurites as these
neurites began or ceased exhibiting calcium overload. The
percentage of neurites with calcium overload in the DA-
9803-treated animals decreased throughout all four im-
aging sessions while the vehicle-treated animals continued
to accumulate neurites exhibiting calcium overload during
this period. The mechanism by which DA-9803 decreased
calcium overload is unclear. However, it is plausible to
speculate that DA-9803 neutralized the toxic Aβ species,
resulting in decreased Aβ40 and Aβ42 levels and a reduc-
tion in amyloid plaque load as described earlier, ultimately
leading to decreased calcium overload. DA-9803
treatment could be affecting processes downstream of
calcium homeostasis, such as restoration of calcium
compartmentalization, calcineurin activity, and/or the
transcriptional factor nuclear factor of activated T cells
(NFAT) localization, all of which have been reported pre-
viously to be disrupted by elevated calcium [36].
Neuroinflammation is believed to be central to the pro-
gression of AD. Modulating the reactivity of astrocytes and
microglia could lead to increased phagocytosis and clear-
ance of Aβ as well as other neurotoxic species in the CNS.
This activity could lead to the prevention of amyloid depos-
ition, increased clearance, and possible downstream effects
on neural function that would include calcium overload,
neuronal degeneration, and deficits in behavioral tasks. We
performed immunohistochemical analyses of reactive glia
in the brains of mice used in the longitudinal imaging ex-
periments. Activation of astrocytes and microglia especially
in close proximity to amyloid plaques have been reported
in animal models of AD as well as brain tissue of AD pa-
tients [14, 25, 37]. Activation of astrocytes and microglia,
specifically around amyloid plaques, were detected in the
current study. However, there was no statistical difference
in the number of either reactive astrocytes or microglia in
the drug-treated animals compared to vehicle-treated mice.
However, further analysis revealed morphological alter-
ations of astrocytes and microglia after DA-9803 treatment.
Shortening of the processes and increases in cell body
diameter could indicate a glial transition to a phagocytic
state [29–31], possibly rendering them more prone to clear-
ing Aβ by internalization of the toxic peptide [38]. This
suggests that chronic treatment of DA-9807 increases a
neuroinflammatory profile that may contribute to Aβ clear-
ance through phagocytosis by glial cells.
Conclusions
In summary, treatment with the botanical therapeutic DA-
9803 restored behavioral deficits, prevented amyloid depos-
ition, and decreased Aβ40 and Aβ42 levels in the cortex.
The treatment also restored calcium homeostasis and pos-
sibly facilitated neuroinflammation which could lead to en-
hanced clearance of Aβ. DA-9803 is a complex extract
containing multiple bioactive ingredients, and as such is
likely to have multiple mechanisms of action. The current
work demonstrates that DA-9803 shows promise in pre-
venting or alleviating AD pathology and pathophysiology.
Future studies will be directed toward characterization of
the bioactive components, pharmacokinetics, potency,
mechanism(s) of action, and toxicity. Considering the ro-
bust effects in the animal models, we believe that further
examination of DA-9803 is warranted as a candidate thera-
peutic approach in AD.
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Additional files
Additional file 1: Figure S1. Showing DA-9803 does not chemically
interfere with the binding of methoxy-XO4 to amyloid plaques. A–C
Fluorescent images of methoxy-XO4 amyloid plaques after preincubation
with (A) DA-9803 (27 sections from one APP/PS1 mouse), (B) PBS (30 sec-
tions from one mouse), and (C) vehicle compound (29 sections from one
mouse). D Fluorescence intensity of individual amyloid plaques across
conditions. Scale bar, 100 μm. Mean ± SEM. (PDF 748 kb)
Additional file 2: Figure S2. Showing methoxy-XO4 stained amyloid
plaque burden and MAP2 immunoreactivity in postmortem hippocampus
after treatment with vehicle or DA-9803. A–C Fluorescent images of MAP2-
positive neurons (A), methoxy-XO4-labeled plaques (B), and colocalization
of MAP2 and methoxy-XO4 (C) in APP/PS1 mice treated daily with the ve-
hicle compound (n = 14 sections from seven mice). D–F Fluorescent images
of MAP2-positive neurons (D), methoxy-XO4-labeled plaques (E), and colo-
calization of MAP2 and methoxy-XO4 (F) in APP/PS1 mice treated daily with
100 mg/kg DA-9803 (n = 17 sections from five mice). Scale bar, 100 μm. G
Percentage of cortex occupied by methoxy-XO4-positive plaques across
conditions. Mean ± SEM. *p < 0.05. (PDF 2111 kb)
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